Eloralintide Reduces Weight By 9.5% to 20.1% for Patients With Obesity

Eloralintide, an investigational once weekly selective amylin receptor agonist, demonstrated superior mean weight reductions from 9.5% to 20.1% compared with 0.4% with the placebo. In a phase 2 trial (NCT06230523), 263 adults with obesity or overweight and at least 1 obesity-related comorbidity were included, and patients did not have diabetes.¹

"Obesity is a complex condition, and no single treatment works for everyone. To truly address each patient's needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them," Liana K. Billings, MD, director of clinical and genetics research in Diabetes and Cardiometabolic Disease at Endeavor Health in Skokie, Illinois, said in a news release.¹ "These phase 2 data suggest eloralintide could offer a promising tolerability profile without compromising on efficacy, underscoring the potential of amylin receptor agonists to expand our therapeutic strategies and better serve individuals living with obesity."

In the study, investigators aimed to determine the weight management efficacy and safety of the investigational drug, with the study spanning 64 weeks and including up to 17 visits. Patients were split into 1 of 7 groups, including eloralintide 1 mg, 3 mg, 6 mg, 9 mg, 6/9 mg (dose escalation), 3/6/9 mg (dose escalation), and the placebo. The primary outcome was the percent change from baseline body weight at 48 weeks, and secondary end points included change from baseline in body weight, percentage of patients who achieved 5% or more and 10% or more body weight reduction, change in body mass index (BMI), and area under the curve and concentration of the drug.²

Between February 5, 2024, and August 14, 2025, patients were included in the study with a mean age of 49 years, a mean bodyweight of 109.1 kg, and a BMI of 39.1 km/m². The mean body weight from baseline after 48 weeks was -9% (1 mg), -12% (3 mg), -18% (6 mg), -20% (9 mg), -20% (6/9 mg), and -16% (3/6/9 mg) compared with -0.4% with the placebo. As for the most common adverse events (AEs), investigators reported nausea and fatigue. Gastrointestinal events were mild to moderate in severity and were seen more frequently in higher-dose arms. The AEs were lower with the slower dose escalations.^1,3

"These data show that eloralintide, a selective amylin receptor agonist, offers the potential for strong efficacy with improved tolerability and could serve as an alternative to incretin therapies,” Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in the news release.¹ “We also are optimistic that it could be a complementary option for patients that need higher levels of efficacy. Based on the encouraging results from Phase 2 trials of eloralintide, we plan to begin Phase 3 enrollment by year-end."

READ MORE: Obesity Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a phase 2 study of adults with obesity or overweight. News release. Eli Lilly. November 6, 2025. Accessed November 12, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated

2. A study of LY3841136 compared with placebo in adult participants with obesity or overweight. ClinicalTrials.gov identification: NCT06230523. Updated August 28, 2025. Accessed November 12, 2025. https://clinicaltrials.gov/study/NCT06230523

3. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. Published online November 6, 2025. doi:10.1016/S0140-6736(25)02155-5